The global urinary tract infection testing market is anticipated to reach $1,027.4 million by 2031, increasing from $574 million in 2021 at a CAGR of 6.2% from 2022 to 2031.
The rise in the prevalence of chronic diseases such as kidney disease and diabetes, an increase in the preference of clinicians for complete urine analysis, the surge in demand for early disease detection, a rise in cases of hospital-acquired urinary tract infection, and an increase in the use of urine analysis tests are the key factors driving the growth of the urinalysis test market. In addition, the rise in demand for minimally invasive urine diagnostic procedures, the increase in adoption of advanced urine analysis testing procedures, and the surge in R&D activities for the introduction of novel and accurate diagnostic tests are some factors that support the growth of the UTI testing market.
The global market for urinary tract infection testing is anticipated to experience development challenges due to side effects associated with the usage of UTI medications. Frequent errors in the diagnosis and management of urinary tract infection testing can impede market expansion during the forecast period. The lack of identifiable symptoms associated with UTI, the absence of standard diagnostic criteria, and the high contamination of samples are some of the key hurdles to market expansion.
Urinary tract infection (UTI) is a common occurrence in females, during pregnancy, and in peri- and postmenopausal women. UTIs are associated with severe morbidity and death, and they impact the quality of life of the affected people. Antibiotic therapy is a successful treatment that shortens the duration of symptoms. The development of resistance, the undesirable effects of antibiotics, and other linked issues lead to the establishment of a research framework to discover alternate means to managing UTIs.
Natural techniques are widely employed in the treatment of numerous ailments to alleviate symptoms and improve overall health.The use of medicinal herbs in the treatment and prevention of numerous diseases has expanded recently]. Complimentary therapy with medicinal herbs is a study topic that may merit special consideration. It has been demonstrated that herbal remedies can be useful in the management of a certain form of UTI.
Treatment with non-antibiotic drugs is a good strategy to lower the chance of developing UTI and to decrease its symptoms. Natural elements, minerals, and probiotics are among several agents that draw interest. Co-formulation of medications in a single dose form can create a natural formulation that is useful for both preventive and therapeutic methods in the management of UTI because each of these medications operates through a separate mechanism.
The COVID-19 pandemic brought several uncertainties, leading to severe economic losses as various businesses across the world were at a standstill. The arrival of the COVID-19 pandemic negatively impacted the manufacturing and supply chain & logistics industries, adversely affecting the healthcare business. Governments and healthcare providers are facing unheard-of issues owing to COVID-19, which has also had an impact on the regulatory environment and procedures. Patients with COVID-19 who were hospitalized were reportedly diagnosed with urinary tract infections. But multiple examinations have revealed that people with COVID-19 did not have severe urinary tract symptoms. Antibiotics are used extensively in COVID-19 patients due to high levels of blood inflammatory indicators of bacterial infection such as elevated C-reactive protein and procalcitonin. The majority of these individuals, however, had microbiologically verified bacterial co-infection symptoms.
The key players profiled in the report include F. Hoffmann-La Roche Ltd, Stryker, Abbott, Siemens, Sysmex Corporation, Cardinal Health, Danaher, Quidel, Bio-Rad Laboratories, Inc., and ACON Labs.
The rise in the prevalence of chronic diseases such as kidney disease and diabetes, an increase in the preference of clinicians for complete urine analysis, the surge in demand for early disease detection, a rise in cases of hospital-acquired urinary tract infection, and an increase in the use of urine analysis tests are the key factors driving the growth of the urinalysis test market. In addition, the rise in demand for minimally invasive urine diagnostic procedures, the increase in adoption of advanced urine analysis testing procedures, and the surge in R&D activities for the introduction of novel and accurate diagnostic tests are some factors that support the growth of the UTI testing market.
The global market for urinary tract infection testing is anticipated to experience development challenges due to side effects associated with the usage of UTI medications. Frequent errors in the diagnosis and management of urinary tract infection testing can impede market expansion during the forecast period. The lack of identifiable symptoms associated with UTI, the absence of standard diagnostic criteria, and the high contamination of samples are some of the key hurdles to market expansion.
Urinary tract infection (UTI) is a common occurrence in females, during pregnancy, and in peri- and postmenopausal women. UTIs are associated with severe morbidity and death, and they impact the quality of life of the affected people. Antibiotic therapy is a successful treatment that shortens the duration of symptoms. The development of resistance, the undesirable effects of antibiotics, and other linked issues lead to the establishment of a research framework to discover alternate means to managing UTIs.
Natural techniques are widely employed in the treatment of numerous ailments to alleviate symptoms and improve overall health.The use of medicinal herbs in the treatment and prevention of numerous diseases has expanded recently]. Complimentary therapy with medicinal herbs is a study topic that may merit special consideration. It has been demonstrated that herbal remedies can be useful in the management of a certain form of UTI.
Treatment with non-antibiotic drugs is a good strategy to lower the chance of developing UTI and to decrease its symptoms. Natural elements, minerals, and probiotics are among several agents that draw interest. Co-formulation of medications in a single dose form can create a natural formulation that is useful for both preventive and therapeutic methods in the management of UTI because each of these medications operates through a separate mechanism.
The COVID-19 pandemic brought several uncertainties, leading to severe economic losses as various businesses across the world were at a standstill. The arrival of the COVID-19 pandemic negatively impacted the manufacturing and supply chain & logistics industries, adversely affecting the healthcare business. Governments and healthcare providers are facing unheard-of issues owing to COVID-19, which has also had an impact on the regulatory environment and procedures. Patients with COVID-19 who were hospitalized were reportedly diagnosed with urinary tract infections. But multiple examinations have revealed that people with COVID-19 did not have severe urinary tract symptoms. Antibiotics are used extensively in COVID-19 patients due to high levels of blood inflammatory indicators of bacterial infection such as elevated C-reactive protein and procalcitonin. The majority of these individuals, however, had microbiologically verified bacterial co-infection symptoms.
The key players profiled in the report include F. Hoffmann-La Roche Ltd, Stryker, Abbott, Siemens, Sysmex Corporation, Cardinal Health, Danaher, Quidel, Bio-Rad Laboratories, Inc., and ACON Labs.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the urinary tract infection testing market analysis from 2021 to 2031 to identify the prevailing urinary tract infection testing market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's Five Forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the urinary tract infection testing market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global urinary tract infection testing market trends, key players, market segments, application areas, and market growth Strategies.
Key Market Segments
By Test Kit
- Home Test Kits
- Laboratory Test Kits
By Infection Type
- Urethritis
- Cystitis
- Pyelonephritis
By Test Type
- Urinalysis
- Urine Cultures
- Susceptibility Testing
By End User
- Hospitals
- Diagnostic Laboratories
- Research Institutes
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- United Arab Emirates
- South Africa
- Rest of LAMEA
Key Market Players
- Thermo Fisher Scientific, Inc.
- Bio-Rad Laboratories
- Danaher Corporation
- ACON Laboratories Inc.
- Cardinal Health Inc.
- Stryker Corporation
- SYSMEX CORPORATION
- Abbott Laboratories
- Roche AG
- LabCorp(Laboratory Corporation of America Holdings).
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. COVID-19 Impact Analysis on the market
3.6. Key Regulation Analysis
3.7. Market Share Analysis
3.8. Patent Landscape
3.9. Regulatory Guidelines
3.10. Value Chain Analysis
CHAPTER 4: URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Urethritis
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Cystitis
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Pyelonephritis
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Urinalysis
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Urine Cultures
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Susceptibility Testing
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: URINARY TRACT INFECTION TESTING MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Diagnostic Laboratories
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Research Institutes
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT
7.1. Overview
7.1.1. Market size and forecast
7.2. Home Test Kits
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Laboratory Test Kits
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
CHAPTER 8: URINARY TRACT INFECTION TESTING MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key trends and opportunities
8.2.2. Market size and forecast, by Infection Type
8.2.3. Market size and forecast, by Test Type
8.2.4. Market size and forecast, by End User
8.2.5. Market size and forecast, by Test Kit
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Key market trends, growth factors and opportunities
8.2.6.1.2. Market size and forecast, by Infection Type
8.2.6.1.3. Market size and forecast, by Test Type
8.2.6.1.4. Market size and forecast, by End User
8.2.6.1.5. Market size and forecast, by Test Kit
8.2.6.2. Canada
8.2.6.2.1. Key market trends, growth factors and opportunities
8.2.6.2.2. Market size and forecast, by Infection Type
8.2.6.2.3. Market size and forecast, by Test Type
8.2.6.2.4. Market size and forecast, by End User
8.2.6.2.5. Market size and forecast, by Test Kit
8.2.6.3. Mexico
8.2.6.3.1. Key market trends, growth factors and opportunities
8.2.6.3.2. Market size and forecast, by Infection Type
8.2.6.3.3. Market size and forecast, by Test Type
8.2.6.3.4. Market size and forecast, by End User
8.2.6.3.5. Market size and forecast, by Test Kit
8.3. Europe
8.3.1. Key trends and opportunities
8.3.2. Market size and forecast, by Infection Type
8.3.3. Market size and forecast, by Test Type
8.3.4. Market size and forecast, by End User
8.3.5. Market size and forecast, by Test Kit
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Key market trends, growth factors and opportunities
8.3.6.1.2. Market size and forecast, by Infection Type
8.3.6.1.3. Market size and forecast, by Test Type
8.3.6.1.4. Market size and forecast, by End User
8.3.6.1.5. Market size and forecast, by Test Kit
8.3.6.2. UK
8.3.6.2.1. Key market trends, growth factors and opportunities
8.3.6.2.2. Market size and forecast, by Infection Type
8.3.6.2.3. Market size and forecast, by Test Type
8.3.6.2.4. Market size and forecast, by End User
8.3.6.2.5. Market size and forecast, by Test Kit
8.3.6.3. France
8.3.6.3.1. Key market trends, growth factors and opportunities
8.3.6.3.2. Market size and forecast, by Infection Type
8.3.6.3.3. Market size and forecast, by Test Type
8.3.6.3.4. Market size and forecast, by End User
8.3.6.3.5. Market size and forecast, by Test Kit
8.3.6.4. Spain
8.3.6.4.1. Key market trends, growth factors and opportunities
8.3.6.4.2. Market size and forecast, by Infection Type
8.3.6.4.3. Market size and forecast, by Test Type
8.3.6.4.4. Market size and forecast, by End User
8.3.6.4.5. Market size and forecast, by Test Kit
8.3.6.5. Italy
8.3.6.5.1. Key market trends, growth factors and opportunities
8.3.6.5.2. Market size and forecast, by Infection Type
8.3.6.5.3. Market size and forecast, by Test Type
8.3.6.5.4. Market size and forecast, by End User
8.3.6.5.5. Market size and forecast, by Test Kit
8.3.6.6. Rest of Europe
8.3.6.6.1. Key market trends, growth factors and opportunities
8.3.6.6.2. Market size and forecast, by Infection Type
8.3.6.6.3. Market size and forecast, by Test Type
8.3.6.6.4. Market size and forecast, by End User
8.3.6.6.5. Market size and forecast, by Test Kit
8.4. Asia-Pacific
8.4.1. Key trends and opportunities
8.4.2. Market size and forecast, by Infection Type
8.4.3. Market size and forecast, by Test Type
8.4.4. Market size and forecast, by End User
8.4.5. Market size and forecast, by Test Kit
8.4.6. Market size and forecast, by country
8.4.6.1. China
8.4.6.1.1. Key market trends, growth factors and opportunities
8.4.6.1.2. Market size and forecast, by Infection Type
8.4.6.1.3. Market size and forecast, by Test Type
8.4.6.1.4. Market size and forecast, by End User
8.4.6.1.5. Market size and forecast, by Test Kit
8.4.6.2. Japan
8.4.6.2.1. Key market trends, growth factors and opportunities
8.4.6.2.2. Market size and forecast, by Infection Type
8.4.6.2.3. Market size and forecast, by Test Type
8.4.6.2.4. Market size and forecast, by End User
8.4.6.2.5. Market size and forecast, by Test Kit
8.4.6.3. India
8.4.6.3.1. Key market trends, growth factors and opportunities
8.4.6.3.2. Market size and forecast, by Infection Type
8.4.6.3.3. Market size and forecast, by Test Type
8.4.6.3.4. Market size and forecast, by End User
8.4.6.3.5. Market size and forecast, by Test Kit
8.4.6.4. South Korea
8.4.6.4.1. Key market trends, growth factors and opportunities
8.4.6.4.2. Market size and forecast, by Infection Type
8.4.6.4.3. Market size and forecast, by Test Type
8.4.6.4.4. Market size and forecast, by End User
8.4.6.4.5. Market size and forecast, by Test Kit
8.4.6.5. Australia
8.4.6.5.1. Key market trends, growth factors and opportunities
8.4.6.5.2. Market size and forecast, by Infection Type
8.4.6.5.3. Market size and forecast, by Test Type
8.4.6.5.4. Market size and forecast, by End User
8.4.6.5.5. Market size and forecast, by Test Kit
8.4.6.6. Rest of Asia-Pacific
8.4.6.6.1. Key market trends, growth factors and opportunities
8.4.6.6.2. Market size and forecast, by Infection Type
8.4.6.6.3. Market size and forecast, by Test Type
8.4.6.6.4. Market size and forecast, by End User
8.4.6.6.5. Market size and forecast, by Test Kit
8.5. LAMEA
8.5.1. Key trends and opportunities
8.5.2. Market size and forecast, by Infection Type
8.5.3. Market size and forecast, by Test Type
8.5.4. Market size and forecast, by End User
8.5.5. Market size and forecast, by Test Kit
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Key market trends, growth factors and opportunities
8.5.6.1.2. Market size and forecast, by Infection Type
8.5.6.1.3. Market size and forecast, by Test Type
8.5.6.1.4. Market size and forecast, by End User
8.5.6.1.5. Market size and forecast, by Test Kit
8.5.6.2. Saudi Arabia
8.5.6.2.1. Key market trends, growth factors and opportunities
8.5.6.2.2. Market size and forecast, by Infection Type
8.5.6.2.3. Market size and forecast, by Test Type
8.5.6.2.4. Market size and forecast, by End User
8.5.6.2.5. Market size and forecast, by Test Kit
8.5.6.3. United Arab Emirates
8.5.6.3.1. Key market trends, growth factors and opportunities
8.5.6.3.2. Market size and forecast, by Infection Type
8.5.6.3.3. Market size and forecast, by Test Type
8.5.6.3.4. Market size and forecast, by End User
8.5.6.3.5. Market size and forecast, by Test Kit
8.5.6.4. South Africa
8.5.6.4.1. Key market trends, growth factors and opportunities
8.5.6.4.2. Market size and forecast, by Infection Type
8.5.6.4.3. Market size and forecast, by Test Type
8.5.6.4.4. Market size and forecast, by End User
8.5.6.4.5. Market size and forecast, by Test Kit
8.5.6.5. Rest of LAMEA
8.5.6.5.1. Key market trends, growth factors and opportunities
8.5.6.5.2. Market size and forecast, by Infection Type
8.5.6.5.3. Market size and forecast, by Test Type
8.5.6.5.4. Market size and forecast, by End User
8.5.6.5.5. Market size and forecast, by Test Kit
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top player positioning, 2021
CHAPTER 10: COMPANY PROFILES
10.1. Abbott Laboratories
10.1.1. Company overview
10.1.2. Key Executives
10.1.3. Company snapshot
10.2. Roche AG
10.2.1. Company overview
10.2.2. Key Executives
10.2.3. Company snapshot
10.3. Thermo Fisher Scientific, Inc.
10.3.1. Company overview
10.3.2. Key Executives
10.3.3. Company snapshot
10.4. Bio-Rad Laboratories
10.4.1. Company overview
10.4.2. Key Executives
10.4.3. Company snapshot
10.5. Danaher Corporation
10.5.1. Company overview
10.5.2. Key Executives
10.5.3. Company snapshot
10.6. ACON Laboratories Inc.
10.6.1. Company overview
10.6.2. Key Executives
10.6.3. Company snapshot
10.7. Cardinal Health Inc.
10.7.1. Company overview
10.7.2. Key Executives
10.7.3. Company snapshot
10.8. Stryker Corporation
10.8.1. Company overview
10.8.2. Key Executives
10.8.3. Company snapshot
10.9. SYSMEX CORPORATION
10.9.1. Company overview
10.9.2. Key Executives
10.9.3. Company snapshot
10.10. LabCorp(Laboratory Corporation of America Holdings).
10.10.1. Company overview
10.10.2. Key Executives
10.10.3. Company snapshot
List of Tables
Table 01. Global Urinary Tract Infection Testing Market, by Infection Type, 2021-2031 (Revenue, $Million)
Table 02. Urinary Tract Infection Testing Market for Urethritis, by Region, 2021-2031 (Revenue, $Million)
Table 03. Urinary Tract Infection Testing Market for Cystitis, by Region, 2021-2031 (Revenue, $Million)
Table 04. Urinary Tract Infection Testing Market for Pyelonephritis, by Region, 2021-2031 (Revenue, $Million)
Table 05. Global Urinary Tract Infection Testing Market, by Test Type, 2021-2031 (Revenue, $Million)
Table 06. Urinary Tract Infection Testing Market for Urinalysis , by Region, 2021-2031 (Revenue, $Million)
Table 07. Urinary Tract Infection Testing Market for Urine Cultures, by Region, 2021-2031 (Revenue, $Million)
Table 08. Urinary Tract Infection Testing Market for Susceptibility Testing, by Region, 2021-2031 (Revenue, $Million)
Table 09. Global Urinary Tract Infection Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 10. Urinary Tract Infection Testing Market for Hospitals, by Region, 2021-2031 (Revenue, $Million)
Table 11. Urinary Tract Infection Testing Market for Diagnostic Laboratories, by Region, 2021-2031 (Revenue, $Million)
Table 12. Urinary Tract Infection Testing Market for Research Institutes, by Region, 2021-2031 (Revenue, $Million)
Table 13. Global Urinary Tract Infection Testing Market, by Test Kit, 2021-2031 (Revenue, $Million)
Table 14. Urinary Tract Infection Testing Market for Home Test Kits, by Region, 2021-2031 (Revenue, $Million)
Table 15. Urinary Tract Infection Testing Market for Laboratory Test Kits, by Region, 2021-2031 (Revenue, $Million)
Table 16. Urinary Tract Infection Testing Market, by Region, 2021-2031 (Revenue, $Million)
Table 17. North America Urinary Tract Infection Testing Market, by Infection Type, 2021-2031 (Revenue, $Million)
Table 18. North America Urinary Tract Infection Testing Market, by Test Type, 2021-2031 (Revenue, $Million)
Table 19. North America Urinary Tract Infection Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 20. North America Urinary Tract Infection Testing Market, by Test Kit, 2021-2031 (Revenue, $Million)
Table 21. North America Urinary Tract Infection Testing Market, by Country, 2021-2031 (Revenue, $Million)
Table 22. U.S. Urinary Tract Infection Testing Market, by Infection Type, 2021-2031 (Revenue, $Million)
Table 23. U.S. Urinary Tract Infection Testing Market, by Test Type, 2021-2031 (Revenue, $Million)
Table 24. U.S. Urinary Tract Infection Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 25. U.S. Urinary Tract Infection Testing Market, by Test Kit, 2021-2031 (Revenue, $Million)
Table 26. Canada Urinary Tract Infection Testing Market, by Infection Type, 2021-2031 (Revenue, $Million)
Table 27. Canada Urinary Tract Infection Testing Market, by Test Type, 2021-2031 (Revenue, $Million)
Table 28. Canada Urinary Tract Infection Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 29. Canada Urinary Tract Infection Testing Market, by Test Kit, 2021-2031 (Revenue, $Million)
Table 30. Mexico Urinary Tract Infection Testing Market, by Infection Type, 2021-2031 (Revenue, $Million)
Table 31. Mexico Urinary Tract Infection Testing Market, by Test Type, 2021-2031 (Revenue, $Million)
Table 32. Mexico Urinary Tract Infection Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 33. Mexico Urinary Tract Infection Testing Market, by Test Kit, 2021-2031 (Revenue, $Million)
Table 34. Europe Urinary Tract Infection Testing Market, by Infection Type, 2021-2031 (Revenue, $Million)
Table 35. Europe Urinary Tract Infection Testing Market, by Test Type, 2021-2031 (Revenue, $Million)
Table 36. Europe Urinary Tract Infection Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 37. Europe Urinary Tract Infection Testing Market, by Test Kit, 2021-2031 (Revenue, $Million)
Table 38. Europe Urinary Tract Infection Testing Market, by Country, 2021-2031 (Revenue, $Million)
Table 39. Germany Urinary Tract Infection Testing Market, by Infection Type, 2021-2031 (Revenue, $Million)
Table 40. Germany Urinary Tract Infection Testing Market, by Test Type, 2021-2031 (Revenue, $Million)
Table 41. Germany Urinary Tract Infection Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 42. Germany Urinary Tract Infection Testing Market, by Test Kit, 2021-2031 (Revenue, $Million)
Table 43. UK Urinary Tract Infection Testing Market, by Infection Type, 2021-2031 (Revenue, $Million)
Table 44. UK Urinary Tract Infection Testing Market, by Test Type, 2021-2031 (Revenue, $Million)
Table 45. UK Urinary Tract Infection Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 46. UK Urinary Tract Infection Testing Market, by Test Kit, 2021-2031 (Revenue, $Million)
Table 47. France Urinary Tract Infection Testing Market, by Infection Type, 2021-2031 (Revenue, $Million)
Table 48. France Urinary Tract Infection Testing Market, by Test Type, 2021-2031 (Revenue, $Million)
Table 49. France Urinary Tract Infection Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 50. France Urinary Tract Infection Testing Market, by Test Kit, 2021-2031 (Revenue, $Million)
Table 51. Spain Urinary Tract Infection Testing Market, by Infection Type, 2021-2031 (Revenue, $Million)
Table 52. Spain Urinary Tract Infection Testing Market, by Test Type, 2021-2031 (Revenue, $Million)
Table 53. Spain Urinary Tract Infection Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 54. Spain Urinary Tract Infection Testing Market, by Test Kit, 2021-2031 (Revenue, $Million)
Table 55. Italy Urinary Tract Infection Testing Market, by Infection Type, 2021-2031 (Revenue, $Million)
Table 56. Italy Urinary Tract Infection Testing Market, by Test Type, 2021-2031 (Revenue, $Million)
Table 57. Italy Urinary Tract Infection Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 58. Italy Urinary Tract Infection Testing Market, by Test Kit, 2021-2031 (Revenue, $Million)
Table 59. Rest of Europe Urinary Tract Infection Testing Market, by Infection Type, 2021-2031 (Revenue, $Million)
Table 60. Rest of Europe Urinary Tract Infection Testing Market, by Test Type, 2021-2031 (Revenue, $Million)
Table 61. Rest of Europe Urinary Tract Infection Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 62. Rest of Europe Urinary Tract Infection Testing Market, by Test Kit, 2021-2031 (Revenue, $Million)
Table 63. Asia-Pacific Urinary Tract Infection Testing Market, by Infection Type, 2021-2031 (Revenue, $Million)
Table 64. Asia-Pacific Urinary Tract Infection Testing Market, by Test Type, 2021-2031 (Revenue, $Million)
Table 65. Asia-Pacific Urinary Tract Infection Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 66. Asia-Pacific Urinary Tract Infection Testing Market, by Test Kit, 2021-2031 (Revenue, $Million)
Table 67. Asia-Pacific Urinary Tract Infection Testing Market, by Country, 2021-2031 (Revenue, $Million)
Table 68. China Urinary Tract Infection Testing Market, by Infection Type, 2021-2031 (Revenue, $Million)
Table 69. China Urinary Tract Infection Testing Market, by Test Type, 2021-2031 (Revenue, $Million)
Table 70. China Urinary Tract Infection Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 71. China Urinary Tract Infection Testing Market, by Test Kit, 2021-2031 (Revenue, $Million)
Table 72. Japan Urinary Tract Infection Testing Market, by Infection Type, 2021-2031 (Revenue, $Million)
Table 73. Japan Urinary Tract Infection Testing Market, by Test Type, 2021-2031 (Revenue, $Million)
Table 74. Japan Urinary Tract Infection Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 75. Japan Urinary Tract Infection Testing Market, by Test Kit, 2021-2031 (Revenue, $Million)
Table 76. India Urinary Tract Infection Testing Market, by Infection Type, 2021-2031 (Revenue, $Million)
Table 77. India Urinary Tract Infection Testing Market, by Test Type, 2021-2031 (Revenue, $Million)
Table 78. India Urinary Tract Infection Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 79. India Urinary Tract Infection Testing Market, by Test Kit, 2021-2031 (Revenue, $Million)
Table 80. South Korea Urinary Tract Infection Testing Market, by Infection Type, 2021-2031 (Revenue, $Million)
Table 81. South Korea Urinary Tract Infection Testing Market, by Test Type, 2021-2031 (Revenue, $Million)
Table 82. South Korea Urinary Tract Infection Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 83. South Korea Urinary Tract Infection Testing Market, by Test Kit, 2021-2031 (Revenue, $Million)
Table 84. Australia Urinary Tract Infection Testing Market, by Infection Type, 2021-2031 (Revenue, $Million)
Table 85. Australia Urinary Tract Infection Testing Market, by Test Type, 2021-2031 (Revenue, $Million)
Table 86. Australia Urinary Tract Infection Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 87. Australia Urinary Tract Infection Testing Market, by Test Kit, 2021-2031 (Revenue, $Million)
Table 88. Rest of Asia-Pacific Urinary Tract Infection Testing Market, by Infection Type, 2021-2031 (Revenue, $Million)
Table 89. Rest of Asia-Pacific Urinary Tract Infection Testing Market, by Test Type, 2021-2031 (Revenue, $Million)
Table 90. Rest of Asia-Pacific Urinary Tract Infection Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 91. Rest of Asia-Pacific Urinary Tract Infection Testing Market, by Test Kit, 2021-2031 (Revenue, $Million)
Table 92. LAMEA Urinary Tract Infection Testing Market, by Infection Type, 2021-2031 (Revenue, $Million)
Table 93. LAMEA Urinary Tract Infection Testing Market, by Test Type, 2021-2031 (Revenue, $Million)
Table 94. LAMEA Urinary Tract Infection Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 95. LAMEA Urinary Tract Infection Testing Market, by Test Kit, 2021-2031 (Revenue, $Million)
Table 96. LAMEA Urinary Tract Infection Testing Market, by Country, 2021-2031 (Revenue, $Million)
Table 97. Brazil Urinary Tract Infection Testing Market, by Infection Type, 2021-2031 (Revenue, $Million)
Table 98. Brazil Urinary Tract Infection Testing Market, by Test Type, 2021-2031 (Revenue, $Million)
Table 99. Brazil Urinary Tract Infection Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 100. Brazil Urinary Tract Infection Testing Market, by Test Kit, 2021-2031 (Revenue, $Million)
Table 101. Saudi Arabia Urinary Tract Infection Testing Market, by Infection Type, 2021-2031 (Revenue, $Million)
Table 102. Saudi Arabia Urinary Tract Infection Testing Market, by Test Type, 2021-2031 (Revenue, $Million)
Table 103. Saudi Arabia Urinary Tract Infection Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 104. Saudi Arabia Urinary Tract Infection Testing Market, by Test Kit, 2021-2031 (Revenue, $Million)
Table 105. United Arab Emirates Urinary Tract Infection Testing Market, by Infection Type, 2021-2031 (Revenue, $Million)
Table 106. United Arab Emirates Urinary Tract Infection Testing Market, by Test Type, 2021-2031 (Revenue, $Million)
Table 107. United Arab Emirates Urinary Tract Infection Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 108. United Arab Emirates Urinary Tract Infection Testing Market, by Test Kit, 2021-2031 (Revenue, $Million)
Table 109. South Africa Urinary Tract Infection Testing Market, by Infection Type, 2021-2031 (Revenue, $Million)
Table 110. South Africa Urinary Tract Infection Testing Market, by Test Type, 2021-2031 (Revenue, $Million)
Table 111. South Africa Urinary Tract Infection Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 112. South Africa Urinary Tract Infection Testing Market, by Test Kit, 2021-2031 (Revenue, $Million)
Table 113. Rest of LAMEA Urinary Tract Infection Testing Market, by Infection Type, 2021-2031 (Revenue, $Million)
Table 114. Rest of LAMEA Urinary Tract Infection Testing Market, by Test Type, 2021-2031 (Revenue, $Million)
Table 115. Rest of LAMEA Urinary Tract Infection Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 116. Rest of LAMEA Urinary Tract Infection Testing Market, by Test Kit, 2021-2031 (Revenue, $Million)
Table 117. Abbott Laboratories: Key Executives
Table 118. Abbott Laboratories: Company Snapshot
Table 119. Roche AG: Key Executives
Table 120. Roche AG: Company Snapshot
Table 121. Thermo Fisher Scientific, Inc.: Key Executives
Table 122. Thermo Fisher Scientific, Inc.: Company Snapshot
Table 123. Bio-Rad Laboratories: Key Executives
Table 124. Bio-Rad Laboratories: Company Snapshot
Table 125. Danaher Corporation: Key Executives
Table 126. Danaher Corporation: Company Snapshot
Table 127. Acon Laboratories Inc.: Key Executives
Table 128. Acon Laboratories Inc.: Company Snapshot
Table 129. Cardinal Health Inc.: Key Executives
Table 130. Cardinal Health Inc.: Company Snapshot
Table 131. Stryker Corporation: Key Executives
Table 132. Stryker Corporation: Company Snapshot
Table 133. Sysmex Corporation: Key Executives
Table 134. Sysmex Corporation: Company Snapshot
Table 135. Labcorp(Laboratory Corporation of America Holdings).: Key Executives
Table 136. Labcorp(Laboratory Corporation of America Holdings).: Company Snapshot
List of Figures
Figure 01. Urinary Tract Infection Testing Market, 2021-2031
Figure 02. Segmentation of Urinary Tract Infection Testing Market, 2021-2031
Figure 03. Top Investment Pockets in Urinary Tract Infection Testing Market (2022-2031)
Figure 04. Porter Five-1
Figure 05. Porter Five-2
Figure 06. Porter Five-3
Figure 07. Porter Five-4
Figure 08. Porter Five-5
Figure 09. Drivers, Restraints and Opportunities: Globalurinary Tract Infection Testing Market
Figure 10. Impact of Key Regulation: Urinary Tract Infection Testing Market
Figure 11. Market Share Analysis: Urinary Tract Infection Testing Market
Figure 12. Patent Analysis by Company
Figure 13. Patent Analysis by Country
Figure 14. Regulatory Guidelines: Urinary Tract Infection Testing Market
Figure 15. Value Chain Analysis: Urinary Tract Infection Testing Market
Figure 16. Urinary Tract Infection Testing Market, by Infection Type, 2021(%)
Figure 17. Comparative Share Analysis of Urinary Tract Infection Testing Market for Urethritis, by Country 2021-2031(%)
Figure 18. Comparative Share Analysis of Urinary Tract Infection Testing Market for Cystitis, by Country 2021-2031(%)
Figure 19. Comparative Share Analysis of Urinary Tract Infection Testing Market for Pyelonephritis, by Country 2021-2031(%)
Figure 20. Urinary Tract Infection Testing Market, by Test Type, 2021(%)
Figure 21. Comparative Share Analysis of Urinary Tract Infection Testing Market for Urinalysis , by Country 2021-2031(%)
Figure 22. Comparative Share Analysis of Urinary Tract Infection Testing Market for Urine Cultures, by Country 2021-2031(%)
Figure 23. Comparative Share Analysis of Urinary Tract Infection Testing Market for Susceptibility Testing, by Country 2021-2031(%)
Figure 24. Urinary Tract Infection Testing Market, by End-user, 2021(%)
Figure 25. Comparative Share Analysis of Urinary Tract Infection Testing Market for Hospitals, by Country 2021-2031(%)
Figure 26. Comparative Share Analysis of Urinary Tract Infection Testing Market for Diagnostic Laboratories, by Country 2021-2031(%)
Figure 27. Comparative Share Analysis of Urinary Tract Infection Testing Market for Research Institutes, by Country 2021-2031(%)
Figure 28. Urinary Tract Infection Testing Market, by Test Kit, 2021(%)
Figure 29. Comparative Share Analysis of Urinary Tract Infection Testing Market for Home Test Kits, by Country 2021-2031(%)
Figure 30. Comparative Share Analysis of Urinary Tract Infection Testing Market for Laboratory Test Kits, by Country 2021-2031(%)
Figure 31. Urinary Tract Infection Testing Market by Region, 2021
Figure 32. U.S. Urinary Tract Infection Testing Market, 2021-2031 ($Million)
Figure 33. Canada Urinary Tract Infection Testing Market, 2021-2031 ($Million)
Figure 34. Mexico Urinary Tract Infection Testing Market, 2021-2031 ($Million)
Figure 35. Germany Urinary Tract Infection Testing Market, 2021-2031 ($Million)
Figure 36. UK Urinary Tract Infection Testing Market, 2021-2031 ($Million)
Figure 37. France Urinary Tract Infection Testing Market, 2021-2031 ($Million)
Figure 38. Spain Urinary Tract Infection Testing Market, 2021-2031 ($Million)
Figure 39. Italy Urinary Tract Infection Testing Market, 2021-2031 ($Million)
Figure 40. Rest of Europe Urinary Tract Infection Testing Market, 2021-2031 ($Million)
Figure 41. China Urinary Tract Infection Testing Market, 2021-2031 ($Million)
Figure 42. Japan Urinary Tract Infection Testing Market, 2021-2031 ($Million)
Figure 43. India Urinary Tract Infection Testing Market, 2021-2031 ($Million)
Figure 44. South Korea Urinary Tract Infection Testing Market, 2021-2031 ($Million)
Figure 45. Australia Urinary Tract Infection Testing Market, 2021-2031 ($Million)
Figure 46. Rest of Asia-Pacific Urinary Tract Infection Testing Market, 2021-2031 ($Million)
Figure 47. Brazil Urinary Tract Infection Testing Market, 2021-2031 ($Million)
Figure 48. Saudi Arabia Urinary Tract Infection Testing Market, 2021-2031 ($Million)
Figure 49. United Arab Emirates Urinary Tract Infection Testing Market, 2021-2031 ($Million)
Figure 50. South Africa Urinary Tract Infection Testing Market, 2021-2031 ($Million)
Figure 51. Rest of LAMEA Urinary Tract Infection Testing Market, 2021-2031 ($Million)
Figure 52. Top Winning Strategies, by Year
Figure 53. Top Winning Strategies, by Development
Figure 54. Top Winning Strategies, by Company
Figure 55. Product Mapping of Top 10 Players
Figure 56. Competitive Dashboard
Figure 57. Competitive Heatmap: Urinary Tract Infection Testing Market
Figure 58. Top Player Positioning, 2021
Executive Summary
According to the report titled, 'Urinary Tract Infection Testing Market,' the urinary tract infection testing market was valued at $574.00 million in 2021, and is estimated to reach $1 billion by 2031, growing at a CAGR of 6.2% from 2022 to 2031.A urinary tract infection (UTI) is an infection of the urinary tract in various parts of excretory system like kidneys, ureters, bladder, and urethra. The urinary system's primary job is to produce urine, which is the system for eliminating water and waste from the body. The kidneys and urine tract are the body's cleaning crew. Women are more likely than men to have a UTI. An infection that is restricted to the bladder can be uncomfortable and irritating. However, if a UTI spreads to the kidneys, it can cause major health concerns. Bacteria, viruses, and fungus are the main causes of urinary tract infections, which mostly affect the urinary tract. Escherichia coli, klebsiella species, pseudomonas aeruginosa, proteus species, and enterococcus species are a few of the bacteria that can cause urinary tract infections.
The high incidence of urinary tract infections worldwide is anticipated to boost the growth of the global market for UTI testing during the forecast period. A microbial pathogen can colonies the bladder or the kidneys and cause a urinary tract infection, which is an infection of the bladder, urethra, ureter, and kidneys. The global market for treating urinary tract infections is anticipated to expand during the forecast period, owing to an increase in the prevalence of diabetes and a rise in the aging population. Urinary tract infections can be particularly problematic for diabetic patients because sugar in the urine provides a favorable environment for the growth of bacteria. Urinary tract infections are more likely to occur in people with diabetes.
Antibiotic-resistant infections and C. diff infections, induce diarrhea that can cause severe colon damage and even lead to death. UTIs (complex UTIs) are anticipated to become more common during the forecast period, owing to the rise in UTI recurrence rates, increase in bacterial resistance in UTI cases, and overuse of antibiotics. The market is likely to expand owing to the rise in the need for new UTI treatments (drugs), which is predicted to happen globally during the forecast period. All these factors are expected to create new growth opportunities for the key players operating in the market.
The urinary tract infection testing market is segmented on the basis of infection type, test type, end user, test kit, and region. On the basis of infection type, the market is classified into urethritis, cystitis, and pyelonephritis. On the basis of test type, the market is divided into urinalysis, urine cultures, and susceptibility testing. On the basis of end-user, the market is classified into hospitals, diagnostic laboratories, and research institutes. By test kit, the market is further divided into home test kits and laboratory test kits. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (UK, Germany, Italy, France, Spain, and rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, United Arab Emirates, South Africa, and rest of LAMEA.
The key players profiled in this report include F. Hoffmann-La Roche Ltd, Stryker, Abbott, Siemens, Sysmex Corporation, Cardinal Health, Danaher, Quidel, Bio-Rad Laboratories, Inc., and ACON Labs. The players in the market have been actively engaged in the adoption of various Strategies such as acquisition, product launch, and expansion to remain competitive and gain an advantage over the competitors in the market. For instance, in June 2019, MiDOG, LLC announced the development of a new urine collection kit and test for the identification of bacterial and fungal diseases in canine uTIs. The market for urinary tract infection testing will expand owing to the introduction of new technologies and the rise in the number of companies offering testing kits and devices.
Key Market Insights
Based on infection type, the cystitis segment accounted for a dominating market share in 2021 and the pyelonephritis segment is estimated to be the fastest growing during the forecast periodBased on test type, the urinalysis segment accounted for a dominating market share in 2021 and is projected to be the fastest growing during the forecast period
Based on end user, the hospitals segment accounted for a dominating market share in 2021 and the diagnostic laboratories segment is estimated to be the fastest growing during the forecast period
Based on test kit, the laboratory test kit segment accounted for a dominating market share in 2021 and is estimated to be the fastest growing during the forecast period
Based on region, North America accounted for the dominant market share by generating a revenue of $230.3 million in 2021 and is projected to account for a significant growth rate during the forecast period
Companies Mentioned
- Thermo Fisher Scientific, Inc.
- Bio-Rad Laboratories
- Danaher Corporation
- ACON Laboratories Inc.
- Cardinal Health Inc.
- Stryker Corporation
- SYSMEX CORPORATION
- Abbott Laboratories
- Roche AG
- LabCorp(Laboratory Corporation of America Holdings).
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
